RESEARCHER PROFILE (Filmed November 2023)
Dr Felicity Han, Research Fellow
Australian Institute for Bioengineering and Nanotechnology
University of Queensland, Australia
Applying nanotechnology to chronic pain management
Dr Felicity Han is a Research Fellow and Leader in Pain Relief Innovation, at the Australian Institute for Bioengineering and Nanotechnology in the University of Queensland. Dr Han’s research interests sit at the interface of drug delivery and the pain field. Her overarching research goal is to improve the quality of day to day life of patients suffering from chronic pain, by applying nanotechnology to the development of novel highly effective pain-killer products for improving chronic pain management.
Dr Han’s team have developed five different techniques to produce painkiller-loaded nanoparticles and nanofibers aimed at improving pain relief for patients where available pain-killers either lack efficacy or produce dose-limiting side-effects. With the use of their nanoparticles, Dr Han’s team aim to turn a small but potent peptide that has been on the market for over a decade into an oral treatment for improving pain management that currently lacks efficacy in patients. T
Dr Han’s research focuses on developing drug-products to solve one of the largest unmet medical needs in the pain field through the use of sustainable materials. Her team are currently working on developing multifunctional sutures including biodegradable pain relief sutures and innovative novel nanoparticles, which deliver innate-immune targeting peptides for the treatment of cancer and cancer-related pain. Their research also investigates the role of C5a and C3a in the pathogenesis of chronic pain including neuropathic pain, cancer-related pain, low back pain, and OA pain.
Dr Han works in collaboration with other leading Australian and international researchers to stay at the forefront of the drug delivery systems field and the pain field. They also provide a preclinical evaluation of novel compounds and formulations.
Dr Han enjoy’s volunteering within the academic community, most notably as Head of the SBMS ECR Committee and Treasurer for The Queensland Chinese Association of Scientists and Engineers (QCASE). Currently, she is serving as a guest editor of Pain Research and Management.
-
Dr Meghan McIlwain
DR MEGHAN MCILWAIN, CLINICAL RESEARCH MANAGER
PRESIDENT, THE NEW ZEALAND ASSOCIATION OF CLINICAL RESEARCH,
AUCKLAND, NEW ZEALAND -
Environmental exposure to function of lung epithelial stem cell biology
Dr Clare Weeden has recently commenced as a Laboratory Head at WEHI in 2025, supported by the CSL Centenary Fellowship.
Dr Weeden specialises in lung epithelial cell biology in the context of homeostasis, inflammation, and lung cancer, particularly in people who don’t smoke. Her work endeavours to understand how past environmental exposures shape the responses of lung cells and the molecular mechanisms underlying this cellular recall, with the aim to develop novel early detection strategies for lung disease.
-
Visceral pain and the gut-brain axis
Professor Stuart Brierley is Director of the Visceral Pain Research Group, Director of the Hopwood Centre for Neurobiology, and Theme co-Leader of Lifelong Health at the South Australian Health and Medical Research Institute (SAHMRI).
Prof Brierley is an international expert on the ‘gut-brain axis’ and chronic visceral pain mechanisms. Current investigations are on a individual cell type called the enterochromaffin cell, and it helps signal pain and anxiety from the gastrointestinal tract to the brain.
